Weekly Research Analysts’ Ratings Updates for Bausch + Lomb (BLCO)

by · The Cerbat Gem

A number of firms have modified their ratings and price targets on shares of Bausch + Lomb (NYSE: BLCO) recently:

  • 9/9/2026 – Bausch + Lomb is now covered by Leerink Partners. They set an “outperform” rating and a $24.00 price target on the stock.
  • 9/9/2026 – Bausch + Lomb is now covered by Leerink Partners. They set an “outperform” rating and a $24.00 price target on the stock.
  • 8/28/2026 – Bausch + Lomb had its “buy” rating reaffirmed by HC Wainwright. They now have a $21.00 price target on the stock.
  • 8/21/2026 – Bausch + Lomb was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
  • 8/7/2026 – Bausch + Lomb was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
  • 8/3/2026 – Bausch + Lomb had its price target raised by HC Wainwright from $20.00 to $21.00. They now have a “buy” rating on the stock.
  • 7/30/2026 – Bausch + Lomb is now covered by UBS Group AG. They set a “buy” rating and a $21.00 price target on the stock.
  • 7/28/2026 – Bausch + Lomb is now covered by UBS Group AG. They set a “buy” rating and a $21.00 price target on the stock.
  • 7/28/2026 – Bausch + Lomb is now covered by UBS Group AG. They set a “buy” rating and a $21.00 price target on the stock.
  • 7/24/2026 – Bausch + Lomb was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Insiders Place Their Bets

In other Bausch + Lomb news, CAO Frederick Munsch sold 52,900 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $16.78, for a total value of $887,662.00. Following the sale, the chief accounting officer directly owned 45,831 shares in the company, valued at $769,044.18. This trade represents a 53.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Eschenbach Andrew C. Von sold 12,500 shares of Bausch + Lomb stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $16.50, for a total value of $206,250.00. Following the sale, the director directly owned 69,792 shares of the company’s stock, valued at $1,151,568. This trade represents a 15.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 71,459 shares of company stock valued at $1,194,370. Insiders own 1.45% of the company’s stock.

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, pharmaceuticals and surgical use. Its portfolio serves consumers, eye-care professionals and patients with a range of products designed to support eye health and improve vision.

The company’s vision-care business includes contact lenses and lens-care products, while its pharmaceutical portfolio includes prescription and over-the-counter treatments for conditions affecting the eyes.

Read More